TSHR and neoplasm: The ineffectiveness of 131I and thyroid-stimulating hormone (TSH) suppression therapy, among other treatments, in managing the tumor can be attributed to the lack of thyroid-stimulating hormone receptors and follicular cells in PSCCT cells (29).